{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T03:47:31Z","timestamp":1795232851996,"version":"4.10.3"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Primary open-angle glaucoma (POAG) is a heritable disease. A polygenic risk score (PRS) threshold may be used to identify individuals at low risk of disease onset.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the utility of a POAG PRS to identify ocular hypertensive individuals at low risk of disease onset.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This is a post hoc analysis of the Ocular Hypertension Treatment Study (OHTS), a multicenter randomized clinical trial across 22 centers in the US conducted among 1636 participants with ocular hypertension from February 1994 to April 2019 with available genetic data. Of the 1636 original participants, 1077 had available genetic data; after excluding 67 for missing data, data quality concerns, or ancestry other than European or African, 1010 were included in the present analysis. Data for this report were analyzed from November 2023 to June 2024.<\/jats:p><\/jats:sec><jats:sec><jats:title>Exposure<\/jats:title><jats:p>From 1994-2002, participants were randomized to receive topical intraocular pressure (IOP)\u2013lowering medications. From 2002 onwards, all participants were given topical IOP-lowering medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcome and Measure<\/jats:title><jats:p>Twenty-year conversion rates by POAG PRS threshold, baseline randomization status, and OHTS clinical risk tertile.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 1010 participants in this study, 563 (65.8%) were female, and the mean (SD) age was 55.9 (9.4) years. In a mixed-effects logistic regression model adjusted for OHTS risk factors for conversion to POAG and randomization status, a PRS under the 48th percentile was associated with a 1.49 times higher likelihood of disease-free status after 20 years of follow-up (95% CI, 1.04-2.15; <jats:italic>P<\/jats:italic>\u2009=\u2009.03; unadjusted hazard ratio [HR], 1.64; 95% CI, 1.13-2.38; <jats:italic>P<\/jats:italic>\u2009=\u2009.009), compared with high polygenic risk. When we stratified the trial cohort into nongenetic OHTS clinical risk tertiles, the largest differences in survival probability at 20 years based on PRS threshold was observed in eyes in the highest tertile, initial observation group (20-year conversion rate: 61.1% in the high polygenic risk group vs 23.8% in the low polygenic risk group; 95% CI, \u221263.0 to \u221211.6; <jats:italic>P<\/jats:italic>\u2009=\u2009.01), with randomization to early treatment partially mitigating the effect of high genetic risk (20-year conversion rate: 37.3% in the high polygenic risk group vs 24.1% in the low polygenic risk group; 95% CI, \u221235.6 to 9.3%; <jats:italic>P<\/jats:italic>\u2009=\u2009.32).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>These findings support considering use of a POAG PRS threshold to identify individuals at low risk of disease onset, with those below the PRS threshold more likely to have lower conversion rates over 20 years. Among those considered at highest risk based on the OHTS clinical risk model, early treatment may partially offset the association with high genetic risk but provide limited benefit for those with low genetic risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT00000125\">NCT00000125<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.4376","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T16:32:08Z","timestamp":1730997128000},"page":"1132","source":"Crossref","is-referenced-by-count":10,"title":["Primary Open-Angle Glaucoma Polygenic Risk Score and Risk of Disease Onset"],"prefix":"10.1001","volume":"142","author":[{"given":"Sayuri","family":"Sekimitsu","sequence":"first","affiliation":[{"name":"Tufts University School of Medicine, Boston, Massachusetts"},{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Ghazal","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanza","family":"Aziz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishabh K.","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Fingert","sequence":"additional","affiliation":[{"name":"Carver College of Medicine, University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mae O.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Kass","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Scheetz","sequence":"additional","affiliation":[{"name":"Carver College of Medicine, University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayellet V.","family":"Segr\u00e8","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"},{"name":"Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis R.","family":"Pasquale","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janey L.","family":"Wiggs","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"},{"name":"Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Brandt","sequence":"additional","affiliation":[{"name":"University of California, Davis, Sacramento"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazlee","family":"Zebardast","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"eoi240066r1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/archopht.117.5.573","article-title":"The Ocular Hypertension Treatment Study: design and baseline description of the participants.","volume":"117","author":"Gordon","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"eoi240066r2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/archopht.120.6.714","article-title":"The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.","volume":"120","author":"Gordon","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"eoi240066r3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"eoi240066r4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaophthalmol.2021.0341","article-title":"Assessment of cumulative incidence and severity of primary open-angle glaucoma among participants in the ocular hypertension treatment study after 20 years of follow-up.","volume":"139","author":"Kass","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"eoi240066r5","doi-asserted-by":"publisher","first-page":"k2820","DOI":"10.1136\/bmj.k2820","article-title":"Overdiagnosis in primary care: framing the problem and finding solutions.","volume":"362","author":"Kale","year":"2018","journal-title":"BMJ"},{"issue":"7","key":"eoi240066r6","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1111\/aos.13758","article-title":"Overdiagnosis of open-angle glaucoma in the general population: the Thessaloniki Eye Study.","volume":"96","author":"Founti","year":"2018","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"eoi240066r7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/gepi.22050","article-title":"Polygenic scores via penalized regression on summary statistics.","volume":"41","author":"Mak","year":"2017","journal-title":"Genet Epidemiol"},{"issue":"9","key":"eoi240066r8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamaophthalmol.2023.3645","article-title":"Deep ocular phenotyping across primary open-angle glaucoma genetic burden.","volume":"141","author":"Sekimitsu","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"eoi240066r9","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1001\/jamaophthalmol.2021.2440","article-title":"Association of monogenic and polygenic risk with the prevalence of open-angle glaucoma.","volume":"139","author":"Siggs","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi240066r10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1001\/jamaophthalmol.2024.0151","article-title":"Polygenic risk scores for glaucoma onset in the ocular hypertension treatment study.","volume":"142","author":"Singh","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"eoi240066r11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1210\/clinem\/dgad530","article-title":"Thyroid cancer polygenic risk score improves classification of thyroid nodules as benign or malignant.","volume":"109","author":"Pozdeyev","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"eoi240066r12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.breast.2023.01.003","article-title":"Polygenic risk scores and breast cancer risk prediction.","volume":"67","author":"Roberts","year":"2023","journal-title":"Breast"},{"issue":"4","key":"eoi240066r13","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1158\/1055-9965.EPI-23-0571","article-title":"Interaction between continuous pack-years smoked and polygenic risk score on lung cancer risk: prospective results from the framingham heart study.","volume":"33","author":"Duncan","year":"2024","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"eoi240066r14","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1016\/j.ophtha.2016.08.036","article-title":"Glaucoma risk alleles in the Ocular Hypertension Treatment Study.","volume":"123","author":"Scheetz","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi240066r15","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/s41467-020-20851-4","article-title":"Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries.","volume":"12","author":"Gharahkhani","year":"2021","journal-title":"Nat Commun"},{"issue":"11","key":"eoi240066r16","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v098.i11","article-title":"cutpointr: improved estimation and validation of optimal cutpoints in R.","volume":"98","author":"Thiele","year":"2021","journal-title":"J Stat Softw"},{"issue":"2","key":"eoi240066r17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"issue":"1","key":"eoi240066r18","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41467-022-29570-4","article-title":"A polygenic risk score for nasopharyngeal carcinoma shows potential for risk stratification and personalized screening.","volume":"13","author":"He","year":"2022","journal-title":"Nat Commun"},{"issue":"6","key":"eoi240066r19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1167\/tvst.10.6.14","article-title":"Risk stratification and clinical utility of polygenic risk scores in ophthalmology.","volume":"10","author":"Qassim","year":"2021","journal-title":"Transl Vis Sci Technol"},{"issue":"2","key":"eoi240066r20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jcjd.2020.06.010","article-title":"Economic evaluation of a new polygenic risk score to predict nephropathy in adult patients with type 2 diabetes.","volume":"45","author":"Guinan","year":"2021","journal-title":"Can J Diabetes"},{"issue":"7","key":"eoi240066r21","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.ophtha.2006.10.031","article-title":"Cost of patients with primary open-angle glaucoma: a retrospective study of commercial insurance claims data.","volume":"114","author":"Lee","year":"2007","journal-title":"Ophthalmology"},{"issue":"suppl1","key":"eoi240066r22","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.4103\/0301-4738.73684","article-title":"Cost-effectiveness of screening for open angle glaucoma in developed countries.","volume":"59","author":"Tuulonen","year":"2011","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"eoi240066r23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/00061198-200002000-00008","article-title":"Which patients are treated for glaucoma? an observational analysis.","volume":"9","author":"Bohn","year":"2000","journal-title":"J Glaucoma"},{"issue":"7","key":"eoi240066r24","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.ophtha.2020.11.024","article-title":"Genetic risk, lifestyle, and age-related macular degeneration in Europe: the EYE-RISK Consortium.","volume":"128","author":"Colijn","year":"2021","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi240066r25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002998","article-title":"Polygenic risk-tailored screening for prostate cancer: a benefit\u2013harm and cost-effectiveness modelling study.","volume":"16","author":"Callender","year":"2019","journal-title":"PLOS Med"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2825836\/jamaophthalmology_sekimitsu_2024_oi_240066_1733957549.02237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T16:02:23Z","timestamp":1734624143000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2825836"}},"subtitle":["A Post Hoc Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.4376","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}